Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezafungin vs Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Allogeneic BMT (ReSPECT)
NCT04368559Phase 3Completed
- Sponsor
- Mundipharma
- Start
- May 2020
- Primary completion
- Jan 2026
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of rezafungin in invasive fungal disease (IFD), sponsored by Mundipharma. Started May 2020; status: completed.
02
Drugs
rezafungin
03
Conditions
invasive fungal disease (IFD)
Beyond the preview
Go deeper on NCT04368559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04368559.